# A Phase 1b Trial in Patients With Renal Cell Cancer

> **NCT01258348** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 21 (actual)

## Conditions studied

- Metastatic Renal Cell Cancer

## Interventions

- **DRUG:** Drug: LY573636-sodium
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01258348
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258348, "A Phase 1b Trial in Patients With Renal Cell Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01258348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*